Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib vs Sorafenib in mRCC
NCT00920816Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2009
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of axitinib in metastatic renal cell carcinoma (mRCC), sponsored by Pfizer. Started Aug 2009; status: completed.
02
Drugs
axitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00920816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920816.